Skip to main content

Table 2 Baseline characteristics and adverse events (AE)

From: A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer

Reference Median age Performance status Stage Weight loss Histology Adverse events (AE)
Jensen et al. [16] 71 years (57-82) NR II: 7%
IIIA: 57%
IIIB: 37%
Weight loss < 5% required Adenocarcinoma: 33%
Squamous: 57%
Other or unknown: 10%
10% died before completing protocol treatment (death unlikely related to treatment), 50% had ≥ grade 3 non-hematologic AE
Jatoi et al. [15] 77 years (60-87) 0: 22%
1: 57%
2: 21%
IIIA: 59%
IIIB: 41%
NR Adenocarcinoma: 38%
Squamous: 43%
Other or unspecified: 19%
No treatment-related deaths, 9% stopped early because of AE, 53% had at least one AE ≥ grade 3
Hallqvist et al. [19] 62 years (42-81) 0: 62%
1: 38%
IIIA: 37%
IIIB: 63%
> 5%: 37% Adenocarcinoma: 49%
Squamous: 39%
Unspecified: 12%
One pneumonitis-related death, 18% did not complete cetuximab and 11% received < 68 Gy, 43% AE ≥ grade 3
Hughes et al. [20] 67.5 years (58-76) 0: 42%
1: 58%
IIIA: 33%
IIIB: 50%
IV: 17%
NR Adenocarcinoma: 33%
Squamous: 50%
Other or unspecified: 17%
One pneumonia-related death, 17% did not complete cetuximab, 17% AE ≥ grade 3
Blumenschein et al. [21] 64 years (42-85) 0: 47%
1: 53%
IIIA: 46%
IIIB: 54%
Weight loss < 5% required NR 6 treatment-related deaths, 20% did not complete RT and concurrent cetuximab, 68% had ≥ grade 3 non-hematologic AE
Govindan et al. [23]* 66 years (32-81) 0: 34%
1: 66%
IIIA: 53%
IIIB: 47%
Weight loss ≤ 10% required Adenocarcinoma: 42%
Squamous: 34%
Other or unspecified: 25%
3 treatment-related deaths, 19% did not complete 4 cycles of CTx and 7 weeks of cetuximab, 62% had ≥ grade 3 non-hematologic AE and 70% ≥ grade 3 hematologic AE
  1. NR: not reported; RT: radiotherapy
  2. *data shown are for patients in the cetuximab arm of this randomised study